Delivery Order SPE2DR25D6028-SPE2DR26FAQQS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $4,244.31 under a firm fixed-price contract type. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, and represents a non-set-aside competitive award. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units) valued at $3,348.66 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to be fulfilled at the vendor's Conshohocken, Pennsylvania facility. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,203.19 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 MG capsules (30-count units) on August 28, 2025, with completion by August 29, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- The Defense Logistics Agency awarded a delivery order valued at $12,137.10 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, which carries no set-aside designation, was competitively awarded and is set for completion by August 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 10.5 mg capsules (30-count units) with a ceiling value of $2,835.01. This competitive award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this order. The award falls under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $43,416.77 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, aligning with AmerisourceBergen's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency (DLA) awarded a $9,609.57 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) under a firm fixed price contract type. The award was made on August 13, 2025, with an ultimate completion date of August 14, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FAQQSDelivery Order
The Defense Logistics Agency awarded a $4,829.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) with an ultimate completion date of November 17, 2025. This non-set-aside award was issued on October 20, 2025, with performance to occur at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this order as a child delivery order under its larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. CAPLYTA is an atypical antipsychotic medication used in the treatment of schizophrenia and bipolar disorder. This delivery order represents a routine pharmaceutical procurement to support military healthcare systems and the Defense Health Agency's medical supply requirements. The award demonstrates AmerisourceBergen Drug Corp's continued capability to supply specialized pharmaceutical products competitively to federal defense healthcare programs through its comprehensive pharmaceutical prime vendor agreement, which enables global distribution of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 10/20/25 |